| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1007710492 |
| P356 | DOI | 10.1186/S13046-016-0350-Y |
| P932 | PMC publication ID | 4855705 |
| P698 | PubMed publication ID | 27141829 |
| P2093 | author name string | Wei Chen | |
| Jie Li | |||
| Xu Li | |||
| Lijie Wang | |||
| Xia Zheng | |||
| Le Zhao | |||
| He Chen | |||
| Jiaojiao Lu | |||
| Xi Han | |||
| Huilian Hou | |||
| Zhongxue Ye | |||
| P2860 | cites work | Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 | Q24306181 |
| Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1 | Q24316558 | ||
| Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine | Q24614582 | ||
| Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies | Q24648438 | ||
| The basics of epithelial-mesenchymal transition | Q24652992 | ||
| The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo | Q24657924 | ||
| Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention | Q26864839 | ||
| Targeting TGF-β signaling in cancer | Q27012443 | ||
| Cancer statistics, 2015 | Q27860576 | ||
| TGF-β regulates DNA methyltransferase expression in prostate cancer, correlates with aggressive capabilities, and predicts disease recurrence | Q28477306 | ||
| Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification | Q28504641 | ||
| Reprogramming of the paternal genome upon fertilization involves genome-wide oxidation of 5-methylcytosine | Q28585429 | ||
| Cancer epigenetics: from mechanism to therapy | Q29614799 | ||
| X inactivation, differentiation, and DNA methylation | Q33999850 | ||
| Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation | Q34258768 | ||
| Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma | Q34299814 | ||
| TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases | Q34301250 | ||
| NANOG-dependent function of TET1 and TET2 in establishment of pluripotency | Q34327015 | ||
| Tumor suppression by miR-26 overrides potential oncogenic activity in intestinal tumorigenesis | Q34590225 | ||
| Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; potential marker of disease recurrence. | Q34762217 | ||
| TGF-β1 induces epigenetic silence of TIP30 to promote tumor metastasis in esophageal carcinoma | Q35273414 | ||
| Clinical significance of DNA methylation mRNA levels of TET family members in colorectal cancer. | Q35749302 | ||
| Global profiling of DNA methylation erasure in mouse primordial germ cells | Q35864711 | ||
| TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells | Q36213724 | ||
| Stage-specific roles for tet1 and tet2 in DNA demethylation in primordial germ cells | Q36934066 | ||
| miR-29 represses the activities of DNA methyltransferases and DNA demethylases | Q37091993 | ||
| Ten-eleven translocation (Tet) and thymine DNA glycosylase (TDG), components of the demethylation pathway, are direct targets of miRNA-29a | Q37157046 | ||
| MicroRNA-26a targets ten eleven translocation enzymes and is regulated during pancreatic cell differentiation | Q37276461 | ||
| An extensive network of TET2-targeting MicroRNAs regulates malignant hematopoiesis | Q37327706 | ||
| miR-30d Blocked Transforming Growth Factor β1-Induced Epithelial-Mesenchymal Transition by Targeting Snail in Ovarian Cancer Cells | Q38824925 | ||
| TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression | Q38832692 | ||
| TET3 mediates the activation of human hepatic stellate cells via modulating the expression of long non-coding RNA HIF1A-AS1. | Q38924188 | ||
| Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas | Q39333118 | ||
| miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-β/Smad3 signaling | Q39413020 | ||
| Involvement of miRNA-29a in epigenetic regulation of transforming growth factor-β-induced epithelial-mesenchymal transition in hepatocellular carcinoma. | Q53101387 | ||
| TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). | Q55036452 | ||
| DNA modification mechanisms and gene activity during development | Q66907977 | ||
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 72 | |
| P577 | publication date | 2016-05-04 | |
| P1433 | published in | Journal of Experimental & Clinical Cancer Research | Q13739415 |
| P1476 | title | TET3 inhibits TGF-β1-induced epithelial-mesenchymal transition by demethylating miR-30d precursor gene in ovarian cancer cells | |
| P478 | volume | 35 |
| Q91717197 | Aberrant hypermethylation-mediated downregulation of antisense lncRNA ZNF667-AS1 and its sense gene ZNF667 correlate with progression and prognosis of esophageal squamous cell carcinoma |
| Q47303229 | CR6-interacting factor 1 inhibits invasiveness by suppressing TGF-β-mediated epithelial-mesenchymal transition in hepatocellular carcinoma |
| Q89514240 | Epigenetic induction of tumor stemness via the lipopolysaccharide-TET3-HOXB2 signaling axis in esophageal squamous cell carcinoma |
| Q90630066 | Expression and prognosis analysis of TET family in acute myeloid leukemia |
| Q90705372 | Glyphosate Primes Mammary Cells for Tumorigenesis by Reprogramming the Epigenome in a TET3-Dependent Manner |
| Q37221246 | Induction of the mesenchymal to epithelial transition by demethylation-activated microRNA-125b is involved in the anti-migration/invasion effects of arsenic trioxide on human chondrosarcoma |
| Q64227434 | Methylation and ovarian cancer: Can DNA methylation be of diagnostic use? |
| Q58788954 | MicroRNA-200 and microRNA-30 family as prognostic molecular signatures in ovarian cancer: A meta-analysis |
| Q92221539 | Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials |
Search more.